List view / Grid view
20 August 2014 | By kdm communications
Syrris is pleased to announce the launch of its state-of-the-art Atlas Cryo Reactor, providing exceptional cooling capability down to -80 °C...
20 August 2014 | By Amgen
Amgen announced that Elliott M. Levy, M.D., has been named senior vice president, Global Development, effective Sept. 8, 2014...
20 August 2014 | By Novartis
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development for compounds to fight tuberculosis that have been discovered at the Novartis Institutes for Tropical Diseases...
19 August 2014 | By Pfizer
Pfizer Inc. announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration for palbociclib...
19 August 2014 | By Novo Nordisk
Novo Nordisk A/S has accepted a DKK 500,000 fine imposed by the Public Prosecutor in a suit filed by the Danish Financial Supervisory Authority and detailed in a press release issued by Novo Nordisk on 10 December 2013...
19 August 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that the first patients have been enrolled in the company’s new international phase III study, RE-DUAL PCI™...
19 August 2014 | By AstraZeneca
AstraZeneca announced positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase III studies investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalised adult patients with complicated intra-abdominal infections...
19 August 2014 | By Amgen
Amgen announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease, receiving hemodialysis, met its primary and all secondary endpoints...
18 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the start of the Phase 3 trial of CHS-0214, an investigational etanercept biosimilar1, in rheumatoid arthritis (the RApsody trial) in Japan...
18 August 2014 | By Biogen Idec
Biogen Idec announced that the U.S. Food and Drug Administration has approved PLEGRIDYTM (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis...
15 August 2014 | By Roche
Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone...
15 August 2014 | By Amgen
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that the Phase 3 clinical trial FOCUS did not meet its primary endpoint of improving overall survival...
15 August 2014 | By Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for bivalent recombinant LP2086...
14 August 2014 | By Sanofi
Sanofi Pasteur announced that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that Fluzone® High-Dose (Influenza Vaccine) was more efficacious in preventing influenza...
14 August 2014 | By AstraZeneca
AstraZeneca announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm...
